Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Silo study advances SPC-15 towards first-in-human trial "Silo has partnered with AmplifyBio since 2022. Our longstanding collaboration has played a key role in advancing SPC-15 through multiple successful pre-clinical studies. A successful IND large animal GLP study is the final study that should facilitate seeking U.S. Food and Drug Administration (FDA) permission for first-inhuman clinical studies in PTSD patients and would constitute a significant milestone achievement for the Company," said Silo CEO Eri ...